Jan 5, 2019 - Health

Pharma plays defense

Illustration: Aïda Amer / Axios

If there’s any area where the Trump administration and a Democratic House majority could find common ground, drug pricing may be it.

Why it matters: Pharma is on its heels, in a way it hasn’t been for years. And it will stay on the defensive for the next two years.

Be smart: President Trump has scrambled all the usual alliances.

On policy, Trump is basically aligned with Democrats, and congressional Republicans are in sync with industry.
Politically, Democrats aren’t inclined to help Trump notch a win on a critically important issue. And congressional Republicans are torn between their donors and their party’s most powerful leader.

Go deeper: These are the pharma companies hiking drug prices in 2019

Go deeper

Ina Fried

8 mins ago - Technology

U.S. pushes homegrown drone industry amid China battle

Illustration: Sarah Grillo/Axios

Alarmed at the prospect of relying on Chinese-made drones for public safety and monitoring critical industries, U.S. investors and the federal government are newly backing a domestic drone industry of hardware and software companies.

The big picture: The moves come as the industry continues to be led by DJI, a Chinese hardware maker — and as concerns grow both in China and the U.S. about reliance on the other country's technology.

Go deeper (2 min. read)

Sara Fischer

21 mins ago - Economy & Business

Exclusive: The N.Y. Times doubles down on TV and film ambitions

Illustration: Aïda Amer/Axios

One of the country's oldest and most established media companies is starting to look more like a Hollywood studio than a traditional newspaper.

Driving the news: The New York Times has 10 scripted TV show projects in development, as well as 3 feature documentaries coming out this year and several other documentary projects in development and production, executives tell Axios.

Go deeper (3 min. read)

Ben Geman

39 mins ago - Energy & Environment

Electric vehicle companies are reeling in cash without producing a car

Illustration: Sarah Grillo/Axios

These are heady days for electric vehicle companies, with a lack of actual car production becoming a popular norm.

Why it matters: The capital infusion is the latest in a busy stretch of deals and market moves that suggest private investors and equity markets see big potential in technologies that now represent a tiny slice of the global vehicle fleet.